ImmuCell Corporation (ICCC)

ImmuCell Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-5.77	-2.49	-0.08	-1.02	-1.3
Depreciation & Amortization	2.72	2.49	2.46	2.35	2.27
Share-Based Compensation	0.37	0.27	0.14	0.25	0.31
Other Operating Activities	-1.99	-1.8	-1.57	-0.26	-1.05
Operating Cash Flow	-4.67	-1.54	0.95	1.32	0.23
Operating Cash Flow Growth	-	-	-27.47%	463.39%	-
Capital Expenditures	-1.89	-3.96	-2.59	-4.03	-0.94
Acquisitions	0	0	0	0	-0.01
Change in Investments	0	0	1	1.46	-2.45
Investing Cash Flow	-1.89	-3.96	-1.6	-2.57	-3.4
Share Issuance / Repurchase	0.02	0.03	4.24	0	8.3
Debt Issued / Paid	1.73	1.08	-0.37	1.91	-1.36
Financing Cash Flow	1.75	1.11	3.88	1.91	6.94
Net Cash Flow	-4.81	-4.39	3.24	0.66	3.77
Free Cash Flow	-6.56	-5.51	-1.64	-2.71	-0.71
Free Cash Flow Margin	-37.57%	-29.66%	-8.52%	-17.67%	-5.16%
Free Cash Flow Per Share	-0.85	-0.71	-0.22	-0.38	-0.10

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).